PDF-(DOWNLOAD)-Ethics and the Pharmaceutical Industry

Despite the pharmaceutical industrys notable contributions to human progress including the development of miracle drugs for treating cancer AIDS and heart disease there is a growing tension between the industry and the public Debates are raging over how the industry can and should be expected to act In this volume leading figures in industry government NGOs the medical community and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior They examine such aspects as the role of intellectual property rights and patent protection the moral and economic requisites of research and clinical trials drug pricing marketing and advertising Michael Santoro is Associate Professor with tenure in the Business Environment Department at Rutgers Business School where he teaches courses on business ethics public policy labor and human rights law ethical issues in the pharmaceutical industry and China business strategy As a Research Associate at Harvard Business School he wrote or coauthored nearly thirty case studies and teaching notes on ethical and legal topics such as global protection of intellectual property insider trading the Federal Sentencing Guidelines and Fair Credit Reporting Act Thomas Gorrie is Corporate Vice President Government Affairs Policy at Johnson Johnson with responsiblity for all federal state and international government affairs and policy He completed postdoctoral studies at the Swiss Federal Institute of Technology in Zurich following the receipt of his doctorate at Princeton University Gorrie has over 30 years of worldwide health care experience and has worked with various Johnson Johnson companies in research and development marketing and sales business development strategic planning general management international venture capital and health policy. March 27th 2014, University of Zurich . Fabienne Heimgartner, Interpharma. What. . it. . needs. . for. . one. . drug. CHF . investment. working. . hours. . experiments. scientists. drug. 1 000 000 000. The Global pharmaceutical industry-part-2. The Framework of five forces.. Potential entrants. Substitutes. Buyers. Suppliers. Implication of the five forces. Potentials entrants “Treat of entry”. version. . : . 21/09/. 2015. Growth and competitiveness of the pharmaceutical industry. www.efpia.eu. Growth & Competitiveness. Growth and competiveness - rationale. Why is the pharmaceutical industry a key asset to European competitiveness ? . Including Key Drivers for change and major trends in this industry. POLITICAL FACTORS. Many countries have a ‘monopsony’ where there is one powerful purchaser; the government. Goverments have focused on pharmaceutical companies as easy targets in their efforts to control rising health care expenditure. Methods include price or reimbursement controls.. version. . : . 21/09/. 2015. Growth and competitiveness of the pharmaceutical industry. www.efpia.eu. Growth & Competitiveness. Growth and competiveness - rationale. Why is the pharmaceutical industry a key asset to European competitiveness ? . Financial Conflicts . of . Interest. A Professional Staff Activity Concerning Financial . Relationships Between Health Care Professionals and Industry. 1. Why Conflicts of Interest Matter. Financial . Human Capital Outlook Implications for Skills Development in the Pharmaceutical Sector. Johannesburg. May 27 2015. Disclaimer . Any views or opinions expressed herein are solely those of the author and do not necessarily represent those of any company. T.U. . Federation of Chemical, Glass and Ceramic. . Industries. . in Poland.. Józef Woźny- . President. National . Pharmaceutical Industry plays an important role in the Polish health & care system provides patients with affordable medicines available to treat most illnesses. . Curtis Smith. November 30, . 2016. Big Data Panel Discussion. Big . Data and the Pharmaceutical Industry. 2. There has been substantial change to the . Pharmaceutical data . environment over the last 5 years. . March 27th 2014, University of Zurich . Fabienne Heimgartner, Interpharma. What. . it. . needs. . for. . one. . drug. CHF . investment. working. . hours. . experiments. scientists. drug. 1 000 000 000. Despite the pharmaceutical industry\'s notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Debates are raging over how the industry can and should be expected to act. In this volume leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, marketing and advertising. . Michael Santoro is Associate Professor with tenure in the Business Environment Department at Rutgers Business School, where he teaches courses on business ethics, public policy, labor and human rights, law, ethical issues in the pharmaceutical industry and China business strategy. As a Research Associate at Harvard Business School, he wrote or co-authored nearly thirty case studies and teaching notes on ethical and legal topics such as global protection of intellectual property, insider trading, the Federal Sentencing Guidelines and Fair Credit Reporting Act. Thomas Gorrie is Corporate Vice President, Government Affairs & Policy, at Johnson & Johnson, with responsiblity for all federal, state and international government affairs and policy. He completed post-doctoral studies at the Swiss Federal Institute of Technology in Zurich, following the receipt of his doctorate at Princeton University. Gorrie has over 30 years of worldwide health care experience and has worked with various Johnson & Johnson companies in research and development, marketing and sales, business development, strategic planning, general management, international, venture capital, and health policy. Despite the pharmaceutical industry\'s notable contributions to human progress, including the development of miracle drugs for treating cancer, AIDS, and heart disease, there is a growing tension between the industry and the public. Debates are raging over how the industry can and should be expected to act. In this volume leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior. They examine such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, marketing and advertising. . Michael Santoro is Associate Professor with tenure in the Business Environment Department at Rutgers Business School, where he teaches courses on business ethics, public policy, labor and human rights, law, ethical issues in the pharmaceutical industry and China business strategy. As a Research Associate at Harvard Business School, he wrote or co-authored nearly thirty case studies and teaching notes on ethical and legal topics such as global protection of intellectual property, insider trading, the Federal Sentencing Guidelines and Fair Credit Reporting Act. Thomas Gorrie is Corporate Vice President, Government Affairs & Policy, at Johnson & Johnson, with responsiblity for all federal, state and international government affairs and policy. He completed post-doctoral studies at the Swiss Federal Institute of Technology in Zurich, following the receipt of his doctorate at Princeton University. Gorrie has over 30 years of worldwide health care experience and has worked with various Johnson & Johnson companies in research and development, marketing and sales, business development, strategic planning, general management, international, venture capital, and health policy. Industry Introduction. Challenges & Opportunities. Industry Introduction. 2010 China’s Health Expenditure was 5.1% of the GDP. From WHO statistic yearbook and . Tengwei. 2013 semiannual summit. Abida Zameer. Harrisburg University. GRAD 699 PGMT. Agenda. Introduction and Problem Statement . Methodology . Results . Discussion. Conclusions. Special . Characterstics. of the pharmaceutical industry .